Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding.

ABSTRACT:

Purpose of review

New therapies are needed to control bleeding in a range of clinical conditions. This review will discuss the biochemical properties of zymogen-like factor Xa, its preclinical assessment in different model systems, and future development prospects.

Recent findings

Underlying many procoagulant therapeutic approaches is the rapid generation of thrombin to promote robust clot formation. Clinically tested prohemostatic agents (e.g., factor VIIa) can provide effective hemostasis to mitigate bleeding in hemophilia and other clinical situations. Over the past decade, we explored the possibility of using zymogen-like factor Xa variants to rapidly improve clot formation for the treatment of bleeding conditions. Compared to the wild-type enzyme, these variants adopt a

SUBMITTER: Thalji NK 

PROVIDER: S-EPMC5629015 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature